133 related articles for article (PubMed ID: 23899983)
1. Incidence and self-management of hand-foot syndrome in patients with colorectal cancer.
Zhao Y; Ding Y; Lu Y; Zhang J; Gu J; Li M
Clin J Oncol Nurs; 2013 Aug; 17(4):434-7. PubMed ID: 23899983
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
3. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
4. Response to "Incidence and self-management of hand-foot syndrome in patients with colorectal cancer".
Llanos EB
Clin J Oncol Nurs; 2014 Apr; 18(2):143. PubMed ID: 24809073
[No Abstract] [Full Text] [Related]
5. [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Suto T; Ishiyama K; Yabuki H; Mori N; Inoue K; Chiba M; Igawa A; Watanabe T; Fujimoto H; Suzuki Y; Sugawara M; Saito T; Kobayashi Y; Matsuda M; Ikeda E; Sato T; Iizawa H
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1729-33. PubMed ID: 20841936
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
[TBL] [Abstract][Full Text] [Related]
7. Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Liu Y; May BH; Zhang AL; Guo X; Lu C; Xue CC; Zhang H
Integr Cancer Ther; 2019; 18():1534735418817833. PubMed ID: 30526124
[TBL] [Abstract][Full Text] [Related]
8. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
11. Incidence and implications of chemotherapy related hand-foot syndrome.
Nikolaou V; Syrigos K; Saif MW
Expert Opin Drug Saf; 2016 Dec; 15(12):1625-1633. PubMed ID: 27718746
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Hsu YH; Shen WC; Wang CH; Lin YF; Chen SC
Eur J Oncol Nurs; 2019 Dec; 43():101670. PubMed ID: 31586645
[TBL] [Abstract][Full Text] [Related]
13. Topical non-occlusive polymers in hand-foot syndrome.
Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
[TBL] [Abstract][Full Text] [Related]
14. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Hoesly FJ; Baker SG; Gunawardane ND; Cotliar JA
Arch Dermatol; 2011 Dec; 147(12):1418-23. PubMed ID: 22184763
[TBL] [Abstract][Full Text] [Related]
16. [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
Matsuyama T; Uetake H; Aoyagi H; Kobayashi H; Ishikawa T; Iida S; Higuchi T; Yasuno M; Enomoto M; Sugihara K
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2147-9. PubMed ID: 19106552
[TBL] [Abstract][Full Text] [Related]
17. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
[TBL] [Abstract][Full Text] [Related]
18. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Lassere Y; Hoff P
Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Jo SJ; Shin H; Jo S; Kwon O; Myung SK
Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
[TBL] [Abstract][Full Text] [Related]
20. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
